BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 172 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $517,236 | +267.5% | 73,056 | +265.5% | 0.00% | – |
Q2 2023 | $140,730 | -38.4% | 19,990 | -27.0% | 0.00% | – |
Q1 2023 | $228,516 | -92.4% | 27,400 | -89.6% | 0.00% | -100.0% |
Q4 2022 | $3,014,705 | +66.8% | 262,605 | +83.1% | 0.01% | +60.0% |
Q3 2022 | $1,807,000 | +678.9% | 143,389 | +554.1% | 0.01% | – |
Q2 2022 | $232,000 | -65.9% | 21,920 | -47.7% | 0.00% | -100.0% |
Q1 2022 | $681,000 | -83.1% | 41,932 | -85.5% | 0.00% | -84.6% |
Q4 2021 | $4,019,000 | -57.9% | 290,122 | -56.4% | 0.01% | -60.6% |
Q3 2021 | $9,553,000 | +4.2% | 664,803 | +14.6% | 0.03% | -8.3% |
Q2 2021 | $9,171,000 | +4049.8% | 580,097 | +1861.6% | 0.04% | +3500.0% |
Q4 2020 | $221,000 | +163.1% | 29,572 | -29.7% | 0.00% | 0.0% |
Q1 2020 | $84,000 | -46.2% | 42,086 | -6.7% | 0.00% | 0.0% |
Q4 2019 | $156,000 | +1633.3% | 45,086 | +3521.4% | 0.00% | – |
Q3 2018 | $9,000 | -97.2% | 1,245 | -96.7% | 0.00% | -100.0% |
Q1 2017 | $317,000 | +1409.5% | 37,700 | +1785.0% | 0.00% | – |
Q4 2015 | $21,000 | -48.8% | 2,000 | -44.4% | 0.00% | – |
Q3 2015 | $41,000 | +485.7% | 3,600 | +620.0% | 0.00% | – |
Q2 2015 | $7,000 | – | 500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
VHCP Management II, LLC | 6,071,142 | $38,430,000 | 18.43% |
RTW INVESTMENTS, LP | 4,078,895 | $25,819,000 | 9.72% |
VHCP Management, LLC | 1,155,104 | $7,312,000 | 7.86% |
RA Capital Management | 2,989,795 | $18,925,000 | 2.68% |
DLD Asset Management, LP | 1,258,700 | $7,967,000 | 2.61% |
Avoro Capital Advisors LLC | 1,631,502 | $10,327,000 | 2.09% |
Ghost Tree Capital, LLC | 1,150,000 | $7,280,000 | 1.75% |
GREAT POINT PARTNERS LLC | 725,000 | $4,589,000 | 0.94% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,237,734 | $20,495,000 | 0.84% |
Baker Brothers Advisors | 10,963,944 | $69,402,000 | 0.68% |